http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2153873-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5489c87cd2b1d905a7497e596824ac6e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate | 1994-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2000-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e160a8d53f9ccb015b88b62f91daedc7 |
| publicationDate | 2000-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2153873-C2 |
| titleOfInvention | Use of ketoconazol and related substances in drugs used for treatment of patients with diabetes mellitus of type-ii |
| abstract | FIELD: medicine, therapy, endocrinology. SUBSTANCE: invention proposes to use ketoconazol and method of conservative treatment of patients with diabetes mellitus of type-II and for neutralization of risk factors that are components of metabolic syndrome (also known as "lethal quartet", "syndrome X", "resistance syndrome to insulin"). Invention relates, in part, to treatment of patients with cardiovascular diseases, stroke, and diabetes mellitus of type-II, resistance to insulin, hyperinsulinemia, abdominal obesity (caused by accumulation of visceral fat), increased level of serum lipids and hypertension, for decrease of liver fat infiltration and for decrease of threat of these diseases and for treatment of patients with cardiovascular diseases, for example, coronaria and other atherosclerotic symptoms including stroke. EFFECT: enhanced effectiveness of treatment. 31 cl, 1 tbl |
| priorityDate | 1994-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 98.